Atrium Medical Corp.: FDA filings under this applicant name
FDA lists 69 510(k) clearances under 2 spellings of the applicant name “Atrium Medical Corp.” (first 1981, latest 2024), plus 1 PMA decision, across 15 product codes in 4 review panels. Median 510(k) review time under this name: 68 days. Related companies, subsidiaries and acquired businesses that file under other applicant names are counted on their own pages, not here.
Caduvo groups this applicant name under Getinge, based on public ownership records.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2012 | 2 | 23 |
| 2013 | 2 | 46 |
| 2014 | 0 | — |
| 2015 | 2 | 120 |
| 2016 | 0 | — |
| 2017 | 0 | — |
| 2018 | 0 | — |
| 2019 | 0 | — |
| 2020 | 0 | — |
| 2021 | 1 | 476 |
| 2022 | 0 | — |
| 2023 | 0 | — |
| 2024 | 1 | 269 |
| 2025 | 0 | — |
| 2026 | 0 | — |
Review time against the same product codes
Since 2017, 510(k)s cleared under the name Atrium Medical Corp. took a median 372 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 109 days.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| DSY | Prosthesis, Vascular Graft, Of 6mm And Greater Diameter | 18 | 18 |
| FTL | Mesh, Surgical, Polymeric | 14 | 14 |
| CAC | Apparatus, Autotransfusion | 10 | 10 |
| KDQ | Bottle, Collection, Vacuum | 8 | 8 |
| DYF | Prosthesis, Vascular Graft, Of Less Then 6mm Diameter | 4 | 4 |
| DQY | Catheter, Percutaneous | 3 | 3 |
| DXE | Catheter, Embolectomy | 3 | 3 |
| DXZ | Patch, Pledget And Intracardiac, Petp, Ptfe, Polypropylene | 2 | 2 |
| JCT | Prosthesis, Tracheal, Expandable | 2 | 2 |
| BTA | Pump, Portable, Aspiration (Manual Or Powered) | 1 | 1 |
Plus 5 more product codes.
Review panels
- Cardiovascular (43)
- General and Plastic Surgery (17)
- General Hospital (8)
- Anesthesiology (2)
Most recent Atrium Medical Corp. 510(k) clearances
| 510(k) | Device | Product code | Decision date | Review days |
|---|---|---|---|---|
| K231972 | Advanta VXT Vascular Graft, Flixene Vascular Graft | DSY | 2024-03-28 | 269 |
| K201305 | Auto transfusion (ATS) Chest Drains: Ocean Water Seal Chest Drain, Oasis Dry Suction Water Seal Chest Drain, Express Dry Seal Chest Drain | CAC | 2021-09-03 | 476 |
| K151386 | C-QUR, C-QUR FX, C-QUR TacShield, C-QUR V-Patch, C-QUR CentriFX, C-QUR Mosaic | FTL | 2015-10-22 | 149 |
| K151437 | ProLite Mesh, ProLite Ultra Mesh, ProLoop Mesh Plug | FTL | 2015-08-27 | 90 |
| K130142 | FLIXENE IFG VASCULAR GRAFT | DSY | 2013-03-15 | 52 |
| K130131 | EDRAIN CHEST DRAINAGE SYSTEM | BTA | 2013-02-28 | 41 |
| K122138 | ATRIUM FLIXENE IFG VASCULAR GRAFT | DSY | 2012-08-17 | 29 |
| K121070 | C-QUR RPM MESH | FTL | 2012-04-26 | 17 |
| K113112 | CLEARWAY RX NB CATHETER | DQY | 2011-11-17 | 28 |
| K110110 | ATRIUM CENTRILFX MESH | FTL | 2011-02-15 | 32 |
59 earlier clearances. See the full list in Caduvo.
PMA and De Novo decisions
| Number | Pathway | Device | Decision date |
|---|---|---|---|
| P120003 | PMA | iCast Covered Stent System | 2023-03-22 |
Recalls
180 product recalls in 32 recall events; 86 initiated in the last five years. Most recent: 2026-08-07.
3 product recalls in 2 recall events filed under other recalling-firm names cite a 510(k) or PMA held under this applicant name; 3 initiated in the last five years. Most often: Maquet Cardiovascular, LLC (2), Mckesson Medical-Surgical Inc. Corporate Office (1).
These recall records list the clearance number, so the device was cleared under this name. The recalling firm may be the same company under another spelling, a company that acquired the product line, a relabeler or a contract manufacturer. They are not added to the count above.
Recalling firms are matched to this applicant name by name only (same normalization), so related entities that recall under another name are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Device clinical trials
An industry sponsor named Atrium Medical Corp. is the lead sponsor of 7 device studies on ClinicalTrials.gov (1 active or recruiting). Most recent:
- NCT07161583: Advanta VXT and Flixene PMCF Registry (Recruiting, started 2025-09-25)
- NCT01673373: Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension (Completed, started 2012-10-23)
- NCT01025869: The Clinical Evaluation of the Cinatra™ Corolimus-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries (Terminated, started 2009-12)
- NCT00978952: Large Diameter Advanta™ V12 Covered Stent Trial for Coarctation of the Aorta (Completed, started 2009-09)
- NCT00804024: ClearWay™ RX Registry Trial (Completed, started 2008-08)
FDA spellings included
FDA records this applicant under 2 spellings (case, punctuation and legal-suffix variants of one name); this page adds them up. Filings per spelling:
- Atrium Medical Corp. (64)
- Atrium Medical Corporation (6)
Frequently asked questions
How many FDA 510(k) clearances are listed under Atrium Medical Corp.?
FDA lists 69 510(k) clearances under 2 spellings of the applicant name “Atrium Medical Corp.” (first 1981, latest 2024), plus 1 PMA decision, across 15 product codes in 4 review panels. Filings under other applicant names, such as subsidiaries, are not included.
How long has FDA taken to clear 510(k)s filed by Atrium Medical Corp.?
The median time from FDA receipt to decision across 510(k)s cleared under the name Atrium Medical Corp. is 68 days.
Which FDA product codes appear under Atrium Medical Corp.?
The most frequent FDA product codes under this applicant name are DSY (Prosthesis, Vascular Graft, Of 6mm And Greater Diameter, 18); FTL (Mesh, Surgical, Polymeric, 14); CAC (Apparatus, Autotransfusion, 10).
Next steps
- See all 69 Atrium Medical Corp. clearances with predicates and recalls
- Run predicate analysis for product code DSY, Atrium Medical Corp.'s most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this data. Data and corrections policy.